• Explore /
  • Poster
  • / Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).

Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).

Abstract Poster

Authors

null

Daisuke Takahari

Department of Gastroenterology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

Daisuke Takahari , Akihito Kawazoe , Nozomu Machida , Keiko Minashi , Yukinori Yamagata , Hiroki Hara , Masashi Wakabayashi , Yu Komura , Akihiro Sato , Takeshi Kuwata , Motohiro Kojima , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT05034887

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4161)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4161

Abstract #

TPS4161

Poster Bd #

146a

Abstract Disclosures

Similar Posters

First Author: Daisuke Takahari

First Author: Antonella Cammarota

First Author: Heather L. McArthur

First Author: Nan Niu